Table 1.
Characteristics of the Study Population
| Favorable Outcome (n=20) | Adverse Outcome (n=16) | P Value | |
|---|---|---|---|
|
| |||
| Birth weight (mean ± SD kg) | 3.2 ± 0.9 | 3.1 ± 0.5 | 0.483 |
|
| |||
| Gestational age (mean ± SD week) | 38.5 ± 1.5 | 39.1 ± 1.2 | 0.192 |
|
| |||
| Gender (n, % male) | 11 (55) | 6 (37.5) | 0.296 |
|
| |||
| APGAR scorea | |||
| -1 minute | 1 (0–4) | 1 (0–2)a | 0.179 |
| -5 minute | 4 (0–7) | 2 (0–4)a | 0.005 |
|
| |||
| Presenting pH | 6.96 (6.6–7.42) | 6.9 (6.59–7.14) | 0.2 |
|
| |||
| Severe encephalopathy (n, %) | 0 (0) | 9 (56) | <0.001 |
|
| |||
| Chorioamnionitis (n, %) | 6 (38)b | 3 (25)c | 0.483 |
|
| |||
| Hour of life at TH initiation | 3:49 (2:24–5:52) | 4:16 (2:50–6:00) | 0.124 |
Data presented as median (range) unless otherwise indicated. Data available for a15/16, b16/20, c12/16 subjects. Bolded text highlights significant differences between outcome groups.